SOURCE: Lombard Medical Technologies PLC

August 27, 2013 03:02 ET

Lombard Medical Technologies PLC: First U.S. patients treated with Aorfix

LONDON--(Marketwired - Aug 27, 2013) -

                Lombard Medical Technologies PLC
                ("Lombard Medical" or "Company")


    Only Endovascular Stent Graft Approved in U.S. for Use in Most
            Challenging Abdominal Aortic Aneurysm Cases

London, UK and Irvine, CA, August 27 2013 - Lombard Medical
Technologies PLC (AIM: LMT), the specialist medical technology company
focused on innovative vascular products, today announces that the first
U.S. patients have been successfully treated with AorfixTM, the Group's
flexible stent graft for the endovascular repair of abdominal aortic
aneurysms (AAAs).

Aorfix was approved by the FDA for commercial sale in the U.S. in
February 2013. The approval included a label indication for thetreatment of
patients with angulations at the neck of the aneurysm from
0 to 90 degrees. Moreover, Aorfix is the only endovascular stent graft
with approved labeling for use in more challenging cases with neck
angulations greater than 60 degrees.

The first U.S. cases using Aorfix included patients with aortic neck
angles significantly greater than 60 degrees that would have previously
required more invasive open surgical AAA repair or "off label" use of
an alternative device not designed to treat patients with this level of
tortuosity in the aorta. The patients were treated by Victor J. Weiss,
M.D., a vascular surgeon at Meriter Hospital in Madison, WI and
Sachinder Hans, M.D. of Henry Ford Hospital in Detroit, respectively.
Kim Hodgson, M.D. of Southern Illinois University School of Medicine,
Division of Vascular Surgery, Springfield, Illinois, also reported a
further case where the patient was successfully treated using Aorfix.
All patients are doing well following the procedures.

Simon Hubbert, Chief Executive Officer of Lombard Medical said:"We are
delighted to see the first patients being treated with Aorfix
since the FDA granted approval earlier this year. Previously these
patients would have received more invasive open surgery repair or would
have been treated using a less flexible endovascular device, unlicensed
to treat high aortic neck angles. Since receiving U.S. FDA approval,
the Company has invested in the right people and worked diligently to
ensure we have the commercial infrastructure and processes in place to
become a significant player in the AAA market in the United States."

Dr. Victor Weiss commented:"The flexible design of Aorfix promises to make
it possible to treat
the most challenging patients and provides a less invasive treatment
option to open surgery repair. Based on my initial experience with
Aorfix, I believe its ease of use and unique design will provide us
with an important new tool to ensure the effectiveness of endovascular
treatment of AAAs."

Dr. Sachinder Hans added:"I was particularly impressed by how Aorfix
conformed to a very
challenging anatomy. This patient had several health issues that
existed prior to the procedure, including poor renal function and heavy
calcium deposits, but we had a very successful outcome due to our
ability to address the AAA in a minimally invasive fashion. Aorfix
provides a new and important addition to the armamentarium of
physicians working with patients with AAAs."


For further information:

Lombard Medical Technologies PLC                 Tel: +44(0)1235 750 800
Simon Hubbert, Chief Executive Officer
Ian Ardill, Chief Financial Officer

Canaccord Genuity Limited                        Tel: +44(0)20 7523 8000
Lucy Tilley / Tim Redfern / Henry Fitzgerald
O'Connor / Dr Julian Feneley

FTI Consulting                                   Tel: +44(0)20 7831 3113
Simon Conway / Susan Stuart / Victoria Foster

Allen & Caron                                    Tel: +1 (949) 474 4300
Matt Clawson

About Abdominal Aortic Aneurysms

AAAs are a balloon-like enlargement of the aorta which, if left
untreated, may rupture and cause death. Approximately 4.5 million
people are living with AAAs in the developed world and each year
600,000 new cases are diagnosed. In the U.S. aortic aneurysm disease is
among the leading cause of death and it is estimated that 1.7 million
people over the age of 55 have an AAA. The market for the repair of
AAAs in the U.S. is valued at more than $600 million annually, and is
forecast to grow to $1.6 billion worldwide by 2015 according to
independent market research.

About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT) is a medical device company
focused on device solutions for the $1.3 billion per annum abdominal
aortic aneurysm (AAA) repair market. The Company's lead product,
Aorfix, is an endovascular stent graft which has been specifically
designed to solve the problems that exist in treating complex tortuous
anatomy, which is often present in advanced AAA disease. Aorfix is the
only stent graft approved for AAA neck angulations of up to 90 degrees
and is currently being commercialized worldwide. Aorfix is the first
AAA stent graft not of U.S. origin to gain FDA approval. The Company is
headquartered in Oxfordshire, England with U.S. operations in Irvine,

Further background on the Company can be found at .

                    This information is provided by RNS
          The company news service from the London Stock Exchange


Contact Information